Molecular Templates. has been granted a patent for T-cell epitope delivering polypeptides that target CD8+ T-cell epitopes to the MHC class I pathway. These molecules aim to enhance cytotoxicity against infected or malignant cells, offering potential treatments for cancers, immune disorders, and microbial infections. GlobalData’s report on Molecular Templates gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Molecular Templates, Peptide pharmacophores was a key innovation area identified from patents. Molecular Templates's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
T-cell epitope delivering polypeptides for targeted cell killing
The granted patent US12037367B2 describes a novel cell-targeting molecule designed for specific binding to extracellular target biomolecules on cell surfaces. The molecule consists of a binding region that can attach to a target biomolecule, coupled with a Shiga toxin effector polypeptide. This polypeptide features an amino acid sequence with at least 90% identity to a specified sequence (SEQ ID NO: 1) and includes several defined amino acid substitutions. Notably, the sequence incorporates at least four endogenous B-cell epitope regions, strategically positioned within the Shiga toxin A subunit. The claims further specify additional amino acid characteristics and sequence identity requirements, enhancing the molecule's specificity and efficacy.
Moreover, the patent outlines various configurations for the binding region, including the possibility of fusing it to the carboxy terminus of the Shiga toxin effector polypeptide to create a continuous polypeptide chain. The binding region can be derived from a range of immunoglobulin-type structures, such as single-domain antibody fragments and bispecific minibodies, among others. The patent also mentions the inclusion of a linker peptide and identifies specific extracellular target biomolecules, such as CD20 and HER2/neu, that the targeting molecule can bind to. Additionally, the claims encompass a pharmaceutical composition that combines the cell-targeting molecule with a suitable excipient or carrier, indicating potential applications in therapeutic contexts.
To know more about GlobalData’s detailed insights on Molecular Templates, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
